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Background
Adrenocortical carcinoma is a rare neoplasm characterized by a high risk of recur-
rence after radical resection. Whether the use of mitotane is beneficial as an adjuvant 
treatment has been controversial. Our aim was to evaluate the efficacy of adjuvant 
mitotane in prolonging recurrence-free survival.
Methods
We performed a retrospective analysis involving 177 patients with adrenocortical 
cancer who had undergone radical surgery at 8 centers in Italy and 47 centers in 
Germany between 1985 and 2005. Adjuvant mitotane was administered to 47 Italian 
patients after radical surgery (mitotane group), whereas 55 Italian patients and 75 Ger-
man patients (control groups 1 and 2, respectively) did not receive adjuvant treatment 
after surgery.
Results
Baseline features in the mitotane group and the control group from Italy were simi-
lar; the German patients were significantly older (P = 0.03) and had more stage I or II 
adrenocortical carcinomas (P = 0.02) than did patients in the mitotane group. Recur-
rence-free survival was significantly prolonged in the mitotane group, as compared 
with the two control groups (median recurrence-free survival, 42 months, as com-
pared with 10 months in control group 1 and 25 months in control group 2). Hazard 
ratios for recurrence were 2.91 (95% confidence interval [CI], 1.77 to 4.78; P<0.001) and 
1.97 (95% CI, 1.21 to 3.20; P = 0.005), respectively. Multivariate analysis indicated that 
mitotane treatment had a significant advantage for recurrence-free survival. Adverse 
events associated with mitotane were mainly of grade 1 or 2, but temporary dose re-
duction was needed in 13% of patients.
Conclusions
Adjuvant mitotane may prolong recurrence-free survival in patients with radically re-
sected adrenocortical carcinoma.
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A drenocortical carcinoma is a rare neoplasm characterized by a dismal prog-nosis, with only 16 to 38% of patients sur-
viving for more than 5 years after diagnosis.1-3 
Although a majority of patients have resectable 
disease at presentation,4-6 as many as 75 to 85% 
have a relapse after radical resection.7,8 This high 
recurrence rate has prompted investigators to con-
sider the use of adjuvant therapy,1-3,9 and mitotane 
(a synthetic derivative of the insecticide dichloro-
diphenyltrichloroethane [DDT]) has been widely 
used for this purpose.10-21 However, available stud-
ies do not provide data as to whether adjuvant mi-
totane is efficacious, mainly because of the low 
statistical power of the studies.
We reviewed the outcome of patients with adre-
nocortical carcinoma who had undergone radical 
surgery at tertiary referral centers in Italy from 
1985 through 2003. During this period, adjuvant 
mitotane treatment was routinely used in some 
centers but not in others, providing an opportunity 
to compare two contemporary groups of patients. 
To control further for potential biases, we included 
a second independent control group for compari-
son with mitotane-treated patients in our analysis, 
a cohort of German patients who were treated with 
surgery only. The primary aim of the study was to 
evaluate the efficacy of adjuvant mitotane in pro-
longing recurrence-free survival; secondary aims 
were assessments of overall survival and adverse 
events.
Me thods
Italian Patients
We performed a retrospective analysis among pa-
tients with adrenocortical carcinoma who had un-
dergone radical surgery between January 1985 and 
December 2003 at eight tertiary referral centers 
in Italy. All patients who had undergone radical 
resections were included in the study. Follow-up 
for this study was closed in December 2004.
Patients had to meet the following inclusion 
criteria: an age of 18 years or older and the avail-
ability of preoperative and postoperative computed 
tomographic (CT) or magnetic resonance imaging 
(MRI) scans. Exclusion criteria were macroscopi-
cally incomplete resection, incomplete tumor stag-
ing, concomitant cancers within the previous 
5 years, clinically significant concomitant disease, 
and adjuvant therapies other than mitotane (che-
motherapy or radiotherapy) after surgery.
Of 131 patients identified, 102 met all entry 
criteria. Of those, 29 patients were excluded: 21 
had undergone an incomplete resection, 3 had 
other concomitant tumors, 4 had undergone other 
adjuvant therapies, and 1 had heart failure.
All data were obtained by reviewing patients’ 
histories, discharge summaries, medical records, 
and source documents. Data were retrieved by 
trained medical personnel using specifically tai-
lored data forms. We collected data on the date of 
diagnosis, the date of surgery, the pathology re-
port, the tumor stage at diagnosis, the hormonal 
workup, details concerning mitotane treatment 
(treatment duration and regimen, side effects, and 
reasons for discontinuation), the date of recur-
rence, and either the date and cause of death or the 
date of the last follow-up visit. The institutional 
ethics committee at each clinical center approved 
the study. All patients provided written informed 
consent.
Complete resection was defined as no evidence 
of macroscopic residual disease on the basis of 
surgical reports, histopathological analysis, and 
postoperative imaging. All histologic diagnoses 
were confirmed by experienced pathologists. In 
89% of the patients, two expert pathologists who 
were unaware of study-group assignments reevalu-
ated the histologic analysis according to the Weiss 
criteria (nuclear atypia, atypical mitoses, frequent 
mitoses, small percentage of clear cells, diffuse 
architecture, necrosis, and the invasion of venous, 
sinusoidal, or capsular structures).22,23 Follow-up 
visits, which included imaging of the chest and 
abdomen, were performed every 6 months until 
either disease progression occurred or the study 
period ended.
Tumor staging at diagnosis was based on im-
aging studies and was corroborated by the find-
ings during surgery. Staging was reported accord-
ing to the McFarlane–Sullivan criteria: stage I, 
a tumor diameter of 5 cm or less; stage II, a tumor 
diameter of more than 5 cm; stage III, tumor 
infiltration of neighboring structures or positive 
lymph nodes; and stage IV, infiltration of neigh-
boring structures and positive lymph nodes or 
distant metastases.24,25 Disease recurrence was 
defined as radiologic evidence of a new lesion dur-
ing follow-up.
Adjuvant mitotane (Lysodren, Bristol-Myers 
Squibb) was routinely recommended at four of the 
Italian centers, whereas patients were followed 
without treatment at the other four centers. Mito-
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tane-related adverse events were graded with the 
use of the National Cancer Institute’s Common 
Terminology Criteria for Adverse Events.26
German Patients
A second control group was derived from the Ger-
man Adrenocortical Carcinoma Registry, which 
contained data for 345 patients at the time of anal-
ysis (August 2006). Clinical data for these patients 
were collected by trained medical personnel using 
structured evaluation forms containing compre-
hensive information on diagnostic procedures, sur-
gical outcomes, and follow-up similar to those used 
to evaluate the Italian study population (further de-
tails are available at www.nebennierenkarzinom.
de). The German Adrenocortical Carcinoma Regis-
try was approved by the ethics committee at the 
University of Würzburg, and patients gave written 
informed consent.
Follow-up data were available for 333 patients. 
Of those, 181 patients who were at least 18 years 
of age presented without distant metastases, and 
148 of these patients had undergone radical sur-
gery with curative intent. Detailed surgical reports 
indicated no residual disease in 111 patients. 
Thirty-six patients were excluded because they had 
undergone adjuvant therapies, including mitotane 
(22 patients; median duration of treatment, 7.5 
months), radiotherapy (7), cytotoxic drugs (1), or 
combinations of these treatments (6). The remain-
ing 75 patients met the inclusion and exclusion 
criteria of the Italian observation group. They had 
undergone radical resection between 1985 and 
2005 in 47 centers throughout Germany. The his-
tologic diagnosis for each patient was made by the 
local pathologist. In 73% of patients, tumor ma-
terial was made available to the study pathologist, 
who confirmed the diagnosis in all cases. Infor-
mation on the functional status of adrenocortical 
carcinoma (whether the tumor was hormone-
secreting) was available for 50 patients.
Outcomes
The primary aim of our study was to compare re-
currence-free survival in patients who received ad-
juvant mitotane therapy after radical resection with 
that of patients who did not receive adjuvant ther-
apy. Secondary outcome measures were overall sur-
vival and adverse events associated with mitotane 
therapy. Recurrence-free survival was measured 
from the date of surgery to the date of recurrence; 
for patients who did not have a relapse, the data 
were censored at the date of the last follow-up visit. 
Overall survival was measured from the date of sur-
gery to the date of death, and the data were cen-
sored at the date of the last follow-up visit.
Statistical Analysis
All statistical analyses were performed with Statis-
tica software (StatSoft). Rates and proportions were 
calculated for categorical data and medians and 
ranges for continuous data. Differences in continu-
ous variables were analyzed by means of the two-
tailed Mann–Whitney U test. For categorical vari-
ables, differences were analyzed by means of the 
chi-square test. Survival curves were computed ac-
cording to the Kaplan–Meier method and were 
compared by means of the log-rank test. A Cox pro-
portional-hazards regression analysis was used to 
assess in univariate and multivariate analyses the 
predictive role of the treatment administered and 
of clinical and pathological variables on disease re-
currence and overall survival. The likelihood ratio 
was used to assess the significance of covariates 
included in each model. Heterogeneity in the effect 
of adjuvant treatment in subgroups of patients was 
evaluated with the use of standard tests for inter-
action. Missing data were dealt with by excluding 
patients from particular analyses if their files did 
not contain data for the required variables. All re-
ported P values are two-sided. P values of less than 
0.05 were considered to indicate statistical signif-
icance.
R esult s
Patients 
The characteristics of patients according to group 
are provided in Table 1. The groups of Italian pa-
tients (the mitotane group and control group 1) 
were evenly distributed with respect to age and 
stage of disease, whereas the German patients 
(control group 2) were significantly older than the 
patients in the mitotane group (P = 0.03). Patients 
with stage IV adrenocortical carcinoma had infil-
tration of adjacent organs; none had distant me-
tastases. A higher proportion of men was present 
in control group 1 than in the mitotane group 
(P = 0.05), whereas sex distribution in control 
group 2 did not differ significantly from that in 
the mitotane group. The mitotane group and con-
trol group 1 were evenly distributed with respect 
to tumor stage, whereas the proportion of adre-
nocortical carcinomas of stage I or II was higher 
The New England Journal of Medicine 
Downloaded from nejm.org on April 25, 2012. For personal use only. No other uses without permission. 
 Copyright © 2007 Massachusetts Medical Society. All rights reserved. 
Adjuvant Mitotane in Adrenocortical Carcinoma
n engl j med 356;23 www.nejm.org june 7, 2007 2375
in control group 2 than in the mitotane group 
(P = 0.02). Of the 152 patients who could be eval-
uated, 50% had secreting tumors, with no major 
difference between groups. The median follow-up 
period after surgery was 56.7 months (range, 12 to 
164) in the mitotane group, 67.6 months (range, 
12 to 161) in control group 1, and 43.0 months 
(range, 9 to 230) in control group 2.
Outcome Results
Recurrence was documented in 23 patients in the 
mitotane group (48.9%), 50 in control group 1 
(90.9%), and 55 in control group 2 (73.3%). Mito-
tane treatment was associated with longer recur-
rence-free survival, as compared with either con-
trol group (Fig. 1A). The median recurrence-free 
survival was 42 months in the mitotane group, 
10 months in control group 1 (P<0.001), and 25 
months in control group 2 (P = 0.005), according 
to the log-rank test.
Death from adrenocortical cancer was report-
ed for 12 patients in the mitotane group (25.5%), 
30 in control group 1 (54.5%), and 31 in control 
group 2 (41.3%). Three patients in the mitotane 
group and one in control group 1 died from other 
causes and had no evidence of recurrence. Me-
Table 1. Baseline Characteristics of the Patients.*
Characteristic
Mitotane 
Group
(N = 47)
Control
Group 1
(N = 55) P Value
Control
Group 2
(N = 75) P Value
Age — yr 0.30 0.03
Median 42 44 47
Range 18–67 21–73 18–83
Sex — no. (%) 0.05 0.1
Male 11 (23.4) 23 (41.8) 27 (36.0)
Female 36 (76.6) 32 (58.2) 48 (64.0)
Tumor stage — no. (%) 0.90 0.02†
I 3 (6.4) 4 (7.3) 9 (12.0)
II 27 (57.4) 31 (56.4) 54 (72.0)
III 11 (23.4) 15 (27.3) 11 (14.7)
IV 6 (12.8) 5 (9.1) 1 (1.3)
Tumor size — cm 0.40 0.50
Median 10.5 10.0 10.0
Range 5.0–22.0 4.0–22.0 3.0–28.0
Functional status of tumor — no. (%)
Total no. of patients evaluated 47 55 50
Secreting tumor 24 (51.1) 22 (40.0) 0.30 30 (60.0) 0.40
Glucocorticoids with or without androgens 22 (46.8) 15 (27.3) 25 (50.0)
Androgens 2 (4.3) 5 (9.1) 4 (8.0)
Aldosterone 0 1 (1.8) 1 (2.0)
Estradiol 0 1 (1.8) 0
Nonsecreting tumor 23 (48.9) 33 (60.0) 20 (40.0)
Weiss score‡
Total no. of patients evaluated 45 46 43
Median (range) 6 (3–9) 6 (3–8) 0.20 5 (2–9) 0.09
* All P values are for comparisons between each control group and the mitotane group. Percentages may not total 100 
because of rounding.
† The P value refers to the overall tumor-stage distribution.
‡ The Weiss score ranges from 0 to 9, with a score higher than 2 indicating the presence of adrenal cancer.
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dian overall survival was 110 months in the mito-
tane group, as compared with 52 months in con-
trol group 1 (P = 0.01) and 67 months in control 
group 2 (P = 0.10), according to the log-rank test 
(Fig. 1B).
Among patients in all the groups, recurrences 
were managed with surgery (56.2%), mitotane 
(70.3%), cytotoxic chemotherapy (42.2%), or other 
therapies (7.5%); these approaches were often used 
in combination. Six of 128 patients with recur-
rence did not receive any specific treatment.
To adjust for imbalances in the distribution of 
potential prognostic factors between comparisons 
of recurrence-free survival and overall survival, two 
multivariate Cox models were fitted to the data, in 
which age, sex, and tumor stage were included 
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Figure 1. Kaplan–Meier Estimates of Recurrence-free Survival and Overall Survival.
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as covariates together with treatment group (mito-
tane group vs. control group 1 vs. control group 2). 
Since data on tumor secretory activity and Weiss 
score were not available for all patients in control 
group 2, two further multivariate models that in-
cluded these two variables were fitted on data for 
the Italian patients. However, since secretory activ-
ity and the Weiss score were not found to be as-
sociated with either recurrence-free or overall sur-
vival and since the inclusion of these variables did 
not modify hazard-ratio estimates, only the results 
of the multivariate analyses of the full data set of 
177 patients are presented (Tables 2 and 3). In the 
univariate analysis, only age was significantly as-
sociated with recurrence-free survival and overall 
survival (P<0.001). After adjustments for age, sex, 
and tumor stage, both the Italian and the German 
control groups showed a higher risk of both recur-
rence (hazard ratio, 3.79; 95% confidence interval 
[CI], 2.27 to 6.32; and hazard ratio, 2.93; 95% CI, 
1.74 to 4.94, respectively) and death (hazard ratio, 
2.47; 95% CI, 1.26 to 4.85; and hazard ratio, 1.96; 
95% CI, 1.00 to 3.87, respectively) than did the 
mitotane group. No heterogeneity in the hazard 
ratios was observed across subgroups of patients 
identified by the prognostic factors included in the 
model (all P values for interaction, >0.2).
Mitotane Dose and Adverse Events
In the mitotane group, 20 patients received 3 to 
5 g daily, and 27 patients received 1 to 3 g daily. 
The median duration of treatment was 29 months 
(range, 6 to 164) with no significant difference be-
tween the two regimens; 21 patients were treated 
for 4 years or more.
The adverse events associated with mitotane 
therapy are listed in Table 4. Grade 3 gastrointes-
tinal events were observed in 15% of patients and 
neurologic grade 3 events in 20% of patients who 
received the higher-dose regimen; neither of these 
problems was seen in patients receiving the lower-
dose regimen. Temporary discontinuation or dose 
reduction was necessary in four patients receiv-
ing higher doses of mitotane and in two patients 
receiving lower doses.
Discussion
Our study suggests a benefit associated with the 
use of adjuvant mitotane therapy after radical re-
Table 2. Predictive Factors for Recurrence-free Survival, According to Univariate and Multivariate Analyses.
Variable Univariate Analysis Multivariate Analysis*
Hazard Ratio 95% CI P Value Hazard Ratio 95% CI P Value
Age† 0.98 0.96–0.99 <0.001 0.97 0.96–0.98 <0.001
Sex‡ 1.20 0.83–1.72 0.33 1.08 0.74–1.58 0.67
Tumor stage 0.27 0.03
I 1 1
II 1.91 0.92–3.95 2.10 1.00–4.28
III 2.14 0.98–4.71 2.45 1.10–5.41
IV 2.22 0.85–5.80 4.34 1.61–11.67
Secreting tumor§ 1.29 0.87–1.90 0.20
Weiss score¶ 0.96 0.61–1.50 0.85
Study group
Mitotane group 1 <0.001 1 <0.001
Control group 1 2.91 1.77–4.78 3.79 2.27–6.32
Control group 2 1.97 1.21–3.20 2.93 1.74–4.94
* The model for the multivariate analysis included age (as a continuous variable), sex (as a dichotomized variable), and 
tumor stage (in four strata) as covariates. No significant interactions between treatment group and age, sex, or tumor 
stage were observed, but the low power of these analyses must be considered, given the small number of events.
† The hazard ratio is for each additional year of age.
‡ Female sex was the reference category.
§ Nonsecreting adrenocortical carcinoma was the reference category.
¶ A Weiss score of 6 (median value) or less was the reference category.
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section of adrenocortical carcinoma. As compared 
with patients treated with mitotane, patients in 
both the Italian and the German control groups 
appeared to have a significantly increased risk of 
recurrence (by factors of 3 and 2, respectively). The 
apparent benefit of mitotane therapy was even more 
marked when multivariate analyses were used. 
Similarly, overall survival appeared to be superior 
in patients receiving adjuvant mitotane.
Our study had certain limitations, since it was 
not a randomized trial. Indeed, potential problems 
such as selection bias, diagnostic bias, stage mi-
gration, and bias in follow-up or ascertainment of 
outcome in observational retrospective series are 
well recognized. To reduce selection bias in the 
Italian centers, we included all consecutive eligible 
patients in the study group of the given center (in 
the mitotane group and control group 1) on the 
basis of the treatment policy of that center, as es-
tablished by specific management algorithms and 
not dependent on the characteristics of patients. 
Control group 2 was derived from a large nation-
wide registry of patients with adrenocortical carci-
noma, and the 75 patients in this group were ex-
tracted from a subgroup of 333 patients for whom 
follow-up data were available. Thus, it is reason-
able to assume that control group 2 was represen-
tative of all patients with resected adrenocortical 
carcinoma in Germany during the study period. 
Furthermore, no patients were excluded on the 
basis of treatment adherence or outcome.
The possibility that patients with different un-
measured characteristics were unevenly distributed 
between the Italian groups or that surgery may 
have been more complete in some centers than in 
others cannot be completely excluded. It should be 
noted, however, that the only difference in the dis-
tribution of known or potential prognostic factors 
between the two groups of Italian patients was 
the higher proportion of male patients in control 
group 1, which is unlikely to have affected the re-
sults, since the sex of patients was not an indepen-
dent predictor of survival. Patients in the German 
control group, in contrast, were older, and more 
had early-stage cancers than did patients in the 
mitotane group. However, these differences would 
have predicted a better prognosis in the German 
control group than in the mitotane group. Accord-
ingly, when adjustments were made for the differ-
ences in the distribution of these factors with the 
use of multivariate analyses, larger hazard-ratio 
estimates were obtained, reinforcing the possibil-
Table 3. Prognostic Factors for Overall Survival, According to Univariate and Multivariate Analyses. 
Variable Univariate Analysis Multivariate Analysis*
Hazard Ratio 95% CI P Value Hazard Ratio 95% CI P Value
Age† 0.98 0.96–1.00 0.05 0.98 0.96–1.00 0.02
Sex‡ 0.90 0.55–1.47 0.68 0.78 0.46–1.33 0.36
Tumor stage 0.26 0.29
I 1 1
II 3.81 0.93–15.68 3.68 0.90–15.23
III 4.47 1.03–19.86 4.22 0.97–18.43
IV 3.54 0.65–19.85 4.40 0.79–24.58
Secreting tumor§ 1.32 0.78–2.24 0.30
Weiss score¶ 1.04 0.57–1.89 0.89
Study group 
Mitotane group 1 0.05 1 0.03
Control group 1 2.28 1.17–4.46 2.47 1.26–4.85
Control group 2 1.73 0.89–3.39 1.96 1.00–3.87
* The model for the multivariate analysis included age (as a continuous variable), sex (as a dichotomized variable), and 
tumor stage (in four strata) as covariates. No significant interactions between treatment group and age, sex, or tumor 
stage were observed, but the low power of these analyses must be considered, given the small number of events.
† The hazard ratio is for each additional year of age.
‡ Female sex was the reference category.
§ Nonsecreting adrenocortical carcinoma was the reference category.
¶ A Weiss score of 6 or less (median value) was the reference category.
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ity that the use of mitotane was associated with a 
true prognostic improvement. Differences in his-
tologic classification among the three groups were 
unlikely, since data from most of the patients were 
reviewed by expert pathologists who all used the 
same classification criteria.22,23 Diagnostic and 
staging protocols were similar in all centers, and 
patients in the three groups underwent surgery 
during the same period. Finally, follow-up was suf-
ficiently complete in the three groups, with only 
six patients lost to follow-up. Thus, as far as can 
be stated in a retrospective study, major biases 
appear to have been minimal.
Our study compared adjuvant mitotane therapy 
with no adjuvant therapy in two groups of similar 
patients, whereas historical controls or no controls 
were used in previous studies.5,7,10-20 Strengths of 
our study include the large number of patients, the 
long duration of follow-up, the use of intention-
to-treat analysis, and the inclusion of two indepen-
dent, concomitant groups of patients who received 
no adjuvant therapy after their initial surgery. Not-
withstanding the retrospective nature of this study, 
which warrants caution in the interpretation of 
its results, the study provides important evidence 
for the efficacy of adjuvant treatment with mito-
tane after radical resection of adrenocortical car-
cinoma.
Adrenocortical carcinoma is a heterogeneous 
disease characterized by a generally dismal prog-
nosis, with few patients having either long recur-
rence-free intervals or overall survival.3,8,27,28 This 
observation points to the importance of identify-
ing prognostic factors. In our study, tumor stage 
did not appear to have significant prognostic val-
ue. However, more advanced stages were associ-
ated with increased risk of either disease recur-
rence or death, and the failure to attain statistical 
significance for overall survival may be due to the 
low number of patients with stage I tumors. In 
addition, the tumor stage may affect prognosis 
primarily as it affects the feasibility of radical 
surgery, which was an inclusion criterion of the 
study. It is known that patients with adrenocor-
tical carcinoma have an extremely poor progno-
sis when surgical removal of the tumor is not 
feasible.2,4-8,15,28
Age was the only consistent prognostic factor 
associated with an improved outcome. However, 
the bulk of previous evidence suggests that age 
does not play a major role in prognosis.8,28-30 
Similarly, the majority of studies have reported no 
correlation between sex and survival,5,7,13,28,30 and 
there is only limited evidence that the Weiss score23 
is predictive of long-term outcome.3,31,32 The func-
tional status of the tumor is also usually not re-
lated to prognosis,1,7,11-13,15,28,30 although in ad-
vanced disease, hypercortisolism may contribute to 
an unfavorable outcome.33
Adjuvant mitotane treatment was associated 
with some adverse events, which may be consid-
ered acceptable, given the disease. However, be-
cause of the retrospective nature of our study, un-
derreporting of adverse events cannot be fully 
excluded. Adverse events were manageable, though 
a temporary reduction of the mitotane dose was 
necessary in some patients. Mitotane was not ter-
minated because of adverse events in any of the 
patients.
In summary, our study indicates that adjuvant 
treatment with mitotane can be administered with 
beneficial effects on outcome in patients with ad-
renocortical carcinoma. We believe that our ret-
rospective analysis should renew interest in adju-
Table 4. Adverse Events.*
Event Grade
1 2 3 4
no. of patients
Hematologic symptom
Leukopenia 4 2 0 0
Constitutional or gastrointestinal symptom
Asthenia or fatigue 17 6 1 0
Diarrhea 8 5 0 0
Nausea or vomiting 13 10 3 0
Anorexia 20 7 0 0
Hepatic symptom
Elevated γ-glutamyltransferase 23 10 7 0
Elevated aspartate or alanine aminotransferase 19 4 0 0
Neurologic symptom
Confusion 4 5 2 0
Ataxia 2 1 4 0
Vertigo 4 5 4 0
Other symptom
Blurred vision 0 1 0 0
Gynecomastia 3 1 0 0
* Adverse events were graded according to the National Cancer Institute’s 
Common Terminology Criteria for Adverse Events. Owing to the adrenolytic 
action of mitotane, all patients received prophylactic glucocorticoid replace-
ment therapy. Therefore, detailed monitoring of mitotane-induced adrenal in-
sufficiency was not performed. Because of the retrospective nature of the study, 
underreporting of low-grade side effects must be considered a possibility.
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vant therapy as a key issue in the treatment of this 
disease. In the future, prospective, randomized 
trials will be needed to confirm that adjuvant mi-
totane treatment is sufficiently effective to be con-
sidered as the standard of care after complete re-
section of adrenocortical carcinoma.
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Appendix
The following investigators contributed two or more patients to the German control group: H. Willenberg, P. Goretzki (University 
Hospital, Düsseldorf); M. Rothmund, P. Langer (University Hospital, Marburg); M. Quinkler, W. Oelkers (University Hospital Charité, 
Berlin); H. Denecke (Leopoldina Hospital, Schweinfurt); H.L. Fehm (University Hospital, Lübeck); M. Morcos (University Hospital, 
Heidelberg); F. Beuschlein (University of Freiburg, Freiburg); M. Brauckhoff (University Hospital, Halle); N. Reisch (University Hospital, 
Munich); K. Muessig (University Hospital, Tübingen); C. Fottner (University Hospital, Mainz); K. Hengst (University Hospital, Mün-
ster); and J. Lübbren (Endokrinologikum, Hamburg). 
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